SARMs
Ligandrol (LGD-4033)
An investigational androgen-receptor modulator with short-term human data on lean mass, hormone suppression and lipids.
Human research / important limitations
Also known as: LGD4033 · ligandrol
Practical use
Applying the explained evidence
- Where it fits
- An investigational androgen-receptor modulator with short-term human data on lean mass, hormone suppression and lipids.
- Put the information into practice
- A change in lean mass is not automatically improved strength, health or long-term performance. Study participants were screened healthy men; the results cannot establish safety of prolonged use, combinations or unverified products.
- Check the exact molecule
- Keep the named molecule separate from a broad category claim. Check whether a finding comes from a human intervention, laboratory mechanism or analytical test before interpreting it as a performance benefit.
- Keep this limit in view
- Too short and small to establish long-term safety or durable physical-function benefits. Excluded people with several relevant health problems.
Overview
LGD-4033 is a nonsteroidal androgen-receptor ligand. Tissue selectivity describes its pharmacology; it does not mean effects are confined to muscle.
Risks and limitations
The trial found suppression of total testosterone, SHBG and HDL cholesterol. No drug-related serious adverse events occurred during this small, short study. FDA separately warns about serious harms from products marketed as SARMs.
How to read this
A change in lean mass is not automatically improved strength, health or long-term performance. Study participants were screened healthy men; the results cannot establish safety of prolonged use, combinations or unverified products.
Research explained
Short-term randomized trial
Who was studied
76 healthy men aged 21–50; 21-day treatment period and five-week follow-up.
What was found
Lean mass increased with exposure; fat mass did not change significantly. Hormone and lipid changes returned to baseline during follow-up.
What it cannot establish
Too short and small to establish long-term safety or durable physical-function benefits. Excluded people with several relevant health problems.
Read the original studySelectivity is not muscle-only action
The trial measured changes beyond lean mass, including hormones and HDL cholesterol. That directly challenges the idea that tissue selectivity means only muscle is affected. Separate the intended mechanism from the full set of observed outcomes.
Supporting sourceReversible during follow-up is a bounded finding
Return toward baseline during five weeks of follow-up describes the participants and exposures studied. It does not guarantee recovery after longer use, combinations or a mislabeled product. The observation is useful, but its boundaries matter.
Supporting sourceCommon questions
Does lean-mass gain establish improved performance?
Not by itself. The measurement includes nonfat tissue and fluid, and must be evaluated alongside functional outcomes. A short early-phase trial cannot establish durable athletic benefit.
Sources
Sources checked 2026-09-28.
General education; not a personal treatment plan.